Prodrug activation and tissue-selective loading. Tenofovir alafenamide (TAF) is a 5′-phosphonoamidate prodrug whose antiviral activity depends entirely on intracellular biotransformation rather than direct inhibition by circulating drug. In cells targeted by HIV — primarily CD4⁺ T lymphocytes and macrophages — cathepsin A (CatA) initiates prodrug hydrolysis by cleaving the carboxyester bond of the phosphonoamidate moiety, releasing a metastable intermediate that undergoes spontaneous intramolecular cyclization and phenol elimination to yield a tenofovir–alanine conjugate. In primary human hepatocytes, carboxylesterase 1 (CES1) is the dominant hydrolase rather than CatA, providing a mechanistic basis for differential prodrug processing across cell types. The TFV–alanine intermediate is subsequently converted to parent tenofovir (TFV) at the acidic pH of the lysosomal compartment, and TFV is then phosphorylated stepwise by cellular kinases to tenofovir diphosphate (TFV-DP), the pharmacologically active nucleotide. This prodrug architecture delivers preferential loading into immune compartments: compared with tenofovir disoproxil fumarate (TDF), TAF produces 7.3-fold higher TFV-DP concentrations in PBMCs and 6.4-fold higher concentrations in lymph nodes, with prolonged intracellular retention exceeding 8 days after a single dose. The clinical consequence is equivalent antiviral potency at a far lower administered dose and substantially reduced plasma TFV exposure, limiting off-target effects on renal tubular cells and bone mineral density. Antiviral activity in CD4⁺ T cells depends directly on intact CatA function: pharmacological CatA inhibition reduces TAF anti-HIV activity in primary human CD4⁺ T lymphocytes by 21-fold.

Reverse transcriptase chain termination by TFV-DP and FTC-TP. TFV-DP acts as an obligate chain-terminating substrate analogue at HIV-1 reverse transcriptase (RT): it is incorporated into nascent viral DNA in place of dATP and, lacking the 3′-hydroxyl group required for chain elongation, terminates viral DNA synthesis at the point of incorporation. Emtricitabine (FTC) undergoes parallel intracellular phosphorylation to its active form, FTC-5′-triphosphate (FTC-TP), a cytidine analogue that competitively antagonises HIV-1 RT by competing with the natural substrate dCTP for incorporation into the growing viral DNA strand. Once incorporated, FTC-TP incorporation into nascent viral DNA terminates elongation by the same 3′-OH–deficient mechanism. Together, TFV-DP and FTC-TP act synergistically to deplete the pool of completed viral DNA available for nuclear import and integration. The principal resistance pathway for FTC involves the RT substitution M184V, which alters RT discrimination of (−)-FTC-TP, shifting nucleotide selection toward less productive incorporation states and reducing inhibitory potency.

Integrase strand transfer inhibition within the intasome. Bictegravir (BIC) is a second-generation integrase strand transfer inhibitor (INSTI) whose primary binding event occurs after HIV integrase (IN) assembles with processed viral DNA to form the intasome. BIC inserts into the IN active site and chelates the catalytic Mg²⁺ ions coordinated by the invariant DDE motif (Asp64, Asp116, Glu152), stabilising an inactive active-site architecture through near-covalent metal interactions. Binding is accompanied by displacement of the 3′ viral DNA nucleotide from its normal stacking position, physically occluding the strand transfer reaction. Additional stability is conferred by Gln148 water-mediated hydrogen bonding to Glu152 and Asp116 within the active site. In biochemical assays, BIC is a selective strand transfer inhibitor with an IC₅₀ of 7.5 nM, with comparatively weak inhibition of upstream 3′-processing (IC₅₀ 241 nM). In infected cells, strand transfer blockade prevents chromosomal integration and diverts viral DNA into abortive circular forms, producing 2-LTR circle accumulation as a diagnostic marker of integration failure. BIC's inhibitory effect is sustained by unusually slow dissociation from the IN–DNA complex: its dissociation half-life of 163 hours from wild-type IN–DNA complexes is the longest among approved INSTIs, producing more durable post-washout antiviral activity than raltegravir or elvitegravir. Combination studies confirm that BIC with both NRTIs is highly synergistic antiviral therapy, with no viral breakthrough observed at 5×EC₉₅ through day 32 of in vitro passage. Once-daily dosing is supported by pharmacokinetics that sustain inhibitory concentrations across the full dosing interval, complementing the long intracellular half-lives of TFV-DP and FTC-TP in target lymphoid cells.